1. Home
  2. NTLA vs DHC Comparison

NTLA vs DHC Comparison

Compare NTLA & DHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

N/A

Current Price

$13.63

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Logo Diversified Healthcare Trust of Beneficial Interest

DHC

Diversified Healthcare Trust of Beneficial Interest

N/A

Current Price

$8.23

Market Cap

2.1B

Sector

Real Estate

ML Signal

N/A

Company Overview

Basic Information
Metric
NTLA
DHC
Founded
2014
1998
Country
United States
United States
Employees
N/A
585
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.1B
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
NTLA
DHC
Price
$13.63
$8.23
Analyst Decision
Buy
Strong Buy
Analyst Count
23
3
Target Price
$20.02
$8.00
AVG Volume (30 Days)
5.6M
1.5M
Earning Date
05-07-2026
05-04-2026
Dividend Yield
N/A
0.53%
EPS Growth
27.43
N/A
EPS
N/A
N/A
Revenue
$67,671,000.00
N/A
Revenue This Year
N/A
$3.13
Revenue Next Year
$62.75
$7.00
P/E Ratio
N/A
N/A
Revenue Growth
16.92
N/A
52 Week Low
$7.95
$3.18
52 Week High
$28.24
$9.14

Technical Indicators

Market Signals
Indicator
NTLA
DHC
Relative Strength Index (RSI) 51.20 48.05
Support Level $11.55 $8.13
Resistance Level $14.02 $9.14
Average True Range (ATR) 0.94 0.31
MACD 0.11 -0.09
Stochastic Oscillator 50.27 10.25

Price Performance

Historical Comparison
NTLA
DHC

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About DHC Diversified Healthcare Trust of Beneficial Interest

Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. The company has two reportable segments: SHOP (Senior Housing Operating Portfolio) and Medical Office and Life Science Portfolio. The SHOP segment includes managed senior living communities providing residential living and care services. The Medical Office and Life Science Portfolio segment consists of properties leased to medical providers and biotechnology laboratories. It generates the majority of its revenue from the SHOP segment.

Share on Social Networks: